What changes in this sector
- Clinical trials
- A drug trial goes through the ethics committee (BASEC portal) and, for categories B and C, through Swissmedic. Both applications can be filed in parallel, but the trial only starts with both approvals. Swissmedic, clinical trials of medicinal products
- Funding path
- The most capital-hungry sector: grants and Innosuisse for proof of concept, then life-science funds that finance phase by phase. Each round is tied to a scientific or clinical result.
- Intellectual property
- For a spin-off, the licence negotiated with the university's technology transfer office is the first document an investor will read.
- What investors look at
- The strength of the preclinical data, patent protection, the clinical development plan and the scientific team.
- Where it happens
- Basel, Biopôle in Lausanne, Campus Biotech in Geneva and the Bio-Technopark Schlieren.
Checked on 5 November 2026. An error or a rule change? Write to us.
Who keeps coming back in rounds
- Venture Kick 5 rounds
- Zürcher Kantonalbank 5 rounds
- Biopôle SA 3 rounds
- EQT Life Sciences 3 rounds
- Eurostars 3 rounds
- FIT Vaud (Innovaud) 3 rounds
Recent rounds
November 2026
- CHF 150,000
- CHF 40,000
- 201 TherapeuticsCHF 150,000
201 Therapeutics, which stems from the University of Basel, is researching liver cancer drugs using organoids derived from patient tumours.
October 2026
- DecodeNAtureCHF 10,000
DecodeNAture rapidly identifies DNA in the field for agriculture, biosecurity and biodiversity monitoring.
- Topadur PharmaAmount not disclosed
Topadur Pharma develops locally acting small molecules for wound healing and fibrosis, including TOP-N53, which is in phase 2a.
- Biodelphis TherapeuticsCHF 100,000
Biodelphis Therapeutics, an EPFL spin-off, couples a small molecule with an antibody to treat osteoporosis without acting on the whole body.
- Atlas BioUSD 10 M
Atlas Bio uses AI to simulate clinical trials and drug behaviour, in order to replace part of phase II trials and animal testing.
- Juturna BioCHF 50,000
Juturna Bio, an EPFL spin-off based at the Campus Biotech, is developing epigenetic therapies to restore the function of ageing brain cells, with Alzheimer's as the first target.
- NouscomUSD 135 M
Nouscom is developing NOUS-209, a neoantigen-based immunotherapy designed to prevent cancers in carriers of Lynch syndrome.
September 2026
- Prevision MedicineUSD 5.4 M
Prevision Medicine tests living tumour cells from patients against a large library of treatments to guide therapy choice in oncology.
- Ferm LabsEUR 3 M
Ferm Labs uses precision fermentation to produce natural, salt-free flavour enhancers from co-products.
- DataHowAmount not disclosed
DataHow provides AI and digital twin solutions for the development and production of pharmaceutical bioprocesses.
Active investors in the sector
- BaseLaunch Accelerator · Seed · Up to CHF 500K
- ACE Ventures VC · Seed and stage not specified across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 3 M to USD 5.4 M
- Angelini Ventures CVC · Series B to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of CHF 26 M to USD 135 M
- Backbone Ventures VC · Pre-seed and stage not specified across recorded rounds · Ticket sizes not disclosed; recorded rounds of CHF 2.4 M to USD 3 M
- Biopôle SA Grant · Non-dilutive funding for start-ups on the Biopôle campus · Up to CHF 90 000 per start-up, plus a CHF 250 000 Pre-Clinical Top-Up
- CDP Venture Capital VC · Series A to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of EUR 3 M to USD 135 M
- Creandum VC · Seed to Series A across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 10 M to USD 40 M
- EQT Life Sciences VC · Series A to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 50 M to USD 152 M
- Eurostars Grant · Non-dilutive R&D grants to consortia across recorded rounds · Eurostars funding of EUR 1 to 1.3 M per consortium (including EUR 772 000 for Terapet)
- Forty51 Ventures VC · Seed across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 3.5 M to USD 5.1 M
- GoHub Ventures VC · Seed across recorded rounds · Ticket sizes not disclosed
- Goldman Sachs Alternatives VC · Series B to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 100 M to USD 152 M
- High-Tech Gründerfonds VC · Pre-seed to Series C, mostly seed, across recorded rounds · Ticket sizes not disclosed; recorded rounds of EUR 3 M to USD 100 M
- Lichtsteiner Foundation Grant · Seed across recorded rounds · Tickets not disclosed; recorded rounds of CHF 1.25 M to USD 5.1 M
- M Ventures CVC · Series A to Series C across recorded rounds · Tickets not disclosed; recorded rounds of USD 50 M to USD 135 M
- Neva SGR VC · Series B to Series C across recorded rounds · Tickets not disclosed; recorded rounds of CHF 26 M to USD 135 M
- Nextech Invest VC · A–B · 5–30M
- Omega Funds VC · Series B and round not specified across recorded rounds · Tickets not disclosed; recorded rounds of USD 152 M to USD 165 M
- Perceptive Advisors VC · Series B and debt financing across recorded rounds · Loan of up to USD 70 M (Distalmotion); equity tickets not disclosed
- Verve Ventures VC · Seed–A · 0.5–10M
- Y Combinator Accelerator · Accelerator programme, then follow-on through to Series A across recorded rounds · Tickets not disclosed
- Zürcher Kantonalbank VC · Pre-seed to growth across recorded rounds · Tickets not disclosed; recorded rounds of CHF 1.7 M to USD 25 M